Top Markets
Coin of the day
Lin BioScience, Inc. Lin BioScience, Inc.

Lin BioScience, Inc.

6696
Clasificación en acciones #5731
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Precio por acción
$29.86
Última sincronización: 2026-08-19
Capitalización bursátil
$2.48B
Cambio (1 día)
4.92%
Cambio (1 año)
502.82%
País
TW
Comercio Lin BioScience, Inc. (6696)

Categoría

Ratio P/B de Lin BioScience, Inc. (6696)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Lin BioScience, Inc., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Lin BioScience, Inc. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH